A 40 year-old man was admitted to our hospital for detailed examination of hypokalemia (2.7mEq/1).
Glucocorticoid-suppressible hyperaldosteronism was described for the first time in 1966 by Surtherland et al. The characteristics of this disease are mild hyperaldosteronism, hyporeninemia, hypokalemia, metabolic alkalosis, hypertension, no excess of urinary 17-hydroxycorticosteroid (17-OHCS) and 17-ketosteroid (17-KS) ,excretion and normalization by the administration of dexamethasone. Since a very young child with the disorder may be normotensive, normokalemic and have a normal plasma or urinary aldosterone, suppressed plasma renin activity (PRA) with a rapid and profound decrease in urinary aldosterone in response to treatment with dexamethasone may be the only demonstrable features . However, no normotensive glucocorticoid-suppressible hyperaldosteronism in an adult has been reported.
We experienced a case of probable normotensive glucocorticoid-suppressible hyperaldosteronism with hypercortisolemia and urine and peripheral blood were nomal. Blood urea nitrogen (BUN), creatinine (Cr) and creatinine clearance (Ccr) were all normal. Serum electrolytes revealed hypokalemia and hypercalcemia. Potassium clearance (Ck) was higher than the upper limit of the normal range. Total cholesterol (TC) was high. A 75 g oral glucose tolerance test (75gGTT) revealed glucose intolerance.
Arterial blood gas analysis revealed metabolic alkalosis and hypoxemia (Table 1) . Chest X ray and electrocardiogram were normal.
Plasma ACTH was determined by radioimmunoassay with an ACTH kit (DPC Co. Ltd., Japan). ACTH labeled with iodine 125 was used as the tracer.
Plasma cortisol was determined by fluorescence polarization immunoassay with a TDx cortisol kit (Dainabot Co.). Plasma renin activity was determined by radioimmunoassay with the method of Haber et al. (1969) . The serum aldosterone concentration was determined by direct radioimmunoassay employing aldosterone labeled with iodine 125 (limura et al., 1977 The ratios of plasma cortisol and PAC of the patient were 3.19 and 3.13, respectively and they were higher than those of the control group (2.67 and 2.75, respectively) ( Fig.1 bottom) . In the 2-hour ambulation test, plasma ACTH and cortisol either did not change or decreased after the ambulation. PRA increased slightly after the stimulations, but PAC did not change (Fig. 5) . A saline infusion test was performed after 2-hour ambulation. 2000ml of 0.9% saline solution was infused intraveneously over a period of 4 hours. PRA and PAC were increased from 2.0ng/ml/hr and 10 ng/dl to 6.8ng/ml/hr and 14ng/dl, respectively, after the ambulation, and then they were decreased to 1.1ng/ml/hr and 6ng/dl, respectively by the saline loading. Plasma ACTH and cortisol were gradually decreased (Fig.2, top) . Blood pressure and serum potassium were not examined. In the combination test with 2-hour ambulation and furosemide, 40mg of furosemide was administrated intraveously and then 2-hour ambulation was performed. PRA and PAC were increased from 3.0ng/ml/hr and 10 ng/dl to 11.7ng/ml/hr and 22ng/dl, respectively. Plasma ACTH and cortisol were increased from below 10pg/dl and 20.2pg/ dl to 37pg/ml and 28.3pg/dl, respectively (Fig.2, bottom) .
A dexamethasone suppression test was performed by orally administering dexamethasone (2mg/day) for four days and then 4mg/day for ten days after which adrenal scintigraphy was performed. The Vol.36, No.6 GLUCOCORTICOID-SUPPRESSIBLE ALDOSTERONISM examination revealed a decrease in urinary 17-OHCS and 17-KS which fell below the lower limit of the normal range following the admistration of dexamethasone (2mg/ day and 4mg/day) (Fig.3) Fig. 5. The circadian rhythm and two hours ambulation test before and after the dexamethasone. The levels of F and PAC were suppressed, circadian rhythm disappeared (top) and the responsiveness of PRA and PAC was reversed (bottom) after dexamethasone administration. ation of isotope in the bilateral adrenal glands 6 days later at the postinjection (not shown).
Serum potassium increased from 2.6 to 3.4mEq/l after admission, but was not normalized.
Serum potassium was normalized after the oral administration of desamethasone but decreased to 2.9mq/l after the administration of dexamethasome was discontinued. Serum sodium was 146 mEq/l when he initially visited our hospital, but serum sodium was decreased to 141 mEq/l after admission and further decreased to 139 mEq/l following dexamethasone ad- However, after two hours in an upright position dexamethasone was administrated, following which PRA increased to 5.3ng/ml/hour after ambulation and it was also higher during dexamethasone administration than under non-administration conditions. Basal PAC decreased following dexamethasone administration but after two hours of ambulation PAC increased again and returned to the normal responses (13ng/dl) (Fig.  5) . After the administration of dexamethasone, potas-sium clearance was also normalized.
Discussion
Glucocorticoid-suppressible hyperaldosteronism is characterized by mild hyperaldosteronism, hyporeninemia, hypokalemia, metabolic alkalosis, hypertension, no excess of urinary 17-OHCS and 17-KS excretion, and these conditions are normalized by administering dexamethasone. reported a very young child with this disorder who had normotension, normokalemia, and normal plasma or urinary aldosterone, and who had suppressed plasma renin activity with a rapid and profound decrease in urinary aldosterone in response to treatment with dexamethasone. Laidlaw's group (1966) and Giebink et al. (1973) described glucocorticoid-suppressible hyperaldosteronism with intermittent excess of both urinary 17-OHCS and 17-KS excretion, which were responsive to glucocorticoid. However, no normotensive glucocorticoidsuppressible hyperaldosteronism in an adult has previously been described.
The findings in our patient did not conform to the criteria of typical glucocorticoid-suppressible hyperaldosteronism . However, hypokalemia, metabolic alkalosis, mild hyperaldosteronism which was dependent on ACTH, and the normalization of these findings after the administration of dexamethasone led us to suspect glucocorticoid-suppressible hyperaldosteronism.
In our patient, hypokalemia was normalized by the dexamethasone administration but primary aldosteronism probably cannot be denied.
Glucocorticoid-responsible primary aldosteronism has been reported by some authors (Fukuchi et al., 1974; Mori et al., 1979; Murabayashi et al., 1983; Kato et al., 1988; Gasa et al., 1989) . In those cases, serum potassium and blood pressure were normalized by the long term administration of dexamethasone.
Our case was not able to be differentiated from those cases by the biochemical and endocrinological findings.
A saline infusion test was performed in our case alone. PAC was decreased by saline infusion. Nugent et al. (1971) and Fukuchi et al. (1973) reported that PAC in primary aldosteronism was not significantly changed by saline infusion.
The decrease in PAC due to saline infusion may differentiate glucocorticoid-suppressible aldosteronism from glucocorticoid-respansive primary aldosteronism.
The urinary aldosterone excretion level was comparatively low in our patient but the mechanism has not been clarified. It is not clear that serum potassium was lower than urinary aldosterone excretion, but the renal tubular receptors may be sensitive to aldosterone.
It was reported earlier that the etiology of the disorder might be characterized by an enhanced adrenal receptor for ACTH in the aldosterone-producing adrenal cells (New et al., 1973; Grim and Weinberger 1980; Gangury et al., 1984) . Moreover, in one case, hyperplasia of the glomerulosa and outer fasciculata with no change in the inner fasciculata or reticularis was demonstrated (Haruyama et al., 1982) . In another case, the zona glomerulosa was hypertrophic, and the outer fasciculata had histological evidence of hyperfunction (Matsuo et al., 1985) . These pathological observations suggest the role of the outer fasciculata in aldosterone secretion in dexamethasone-suppressible hyperaldosteronism. Gomez-Sanchez (1986) reported that aldosterone was secreted from the outer fasciculata, was controlled similar to cortisol by ACTH and was exceedingly responsive to ACTH in dexamethasone-suppressible hyperaldosteronism.
Hypercortisolemia and the excess of urinary 17-OHCS and 17-KS excretion were associated with our case. Laidlaw's group (1966) and Giebink et al. (1973) described glucocorticoid-suppressible hyperaldosteronism with intermittent excess of both urinary 17-OHCS and 17-KS but no case with persistent excess of both urinary 17-OHCS and 17-KS has been reported. In the former case, both urinary 17-OHCS and 17-KS were normalized before glucocorticoid treatment.
In the later case, urinary 17-OHCS was suppressed but urinary 17-KS and 17-KGS remained high after dexamethasone administration. Giebink et al. (1973) said that whether the adrenal pathology was adenoma or hyperplasia was yet to be determined in hyperaldosteronism, but it would appear that hyperplasia and adenoma might be a continuum, since the pathology of both might be seen in the same gland or the same patient (Omae et al., 1971 ). In our patient, both urinary 17-OHCS and 17-KS were suppressed by the administration of a low dose of dexamethasone and were increased by the discontinuation of dexamethasone. Our case may be associated with hyperplasia not only of outer fasciculata bu also of inner fasciculata.
The reason for the absence of Cushinggoid symptoms is not clear but a possible genetically determined hyposensitivity to the glucocorticoid action of cortisol is postulated (Vingerhoeds et al., 1976) .
We believe that this case may be a normotensive glucocorticoid-suppressible hyperaldosteronism and that it may be the early stage of the disorder bacause of the normal plasma volume. The etiology which was not associated with hyporeninemia or hypertension has not been clarified but may be related to the shortness of duration of this disease. Further investigation will be required to follow up in the long term and to examine other cases similar to this.
